Blog

Averica Answers – What is Averica’s Approach to Impurity Isolation?

In this video, Paul Lefebvre discusses Averica’s approach for targeted isolation of impurities.   The stability indicating method is the gold standard for figuring out what’s what.  That’s what the customer is using to identify and quantify all the impurities that they have.  What we do is we kind of squish everything together, process a lot of material really fast, and chop it up.  Then we take the pieces and we analyze them by the gold standard.  And, we see …

Continue reading

Averica Discovery Expands Capabilities and Capacity by 50%

Enhances ability to supply early drug development programs while shorteningproject timelines MARLBOROUGH, MA, June 2, 2016 – Averica Discovery Services Inc., an analytical development contract research organization (CRO), today announced new hires and the acquisition of new equipment that significantly expands the Company’s capacity and capability.  Averica offers analytical development services to pharmaceutical companies; supporting new drug profiling, early to mid-stage clinical development, and CMC. Averica filled three new laboratory positions, and added new instrument systems: a new preparative Supercritical Fluid …

Continue reading

5 Ways to Prevent Impurity Isolation Scope Creep

Contracting tough projects with a CRO always requires active management, but some projects are complex enough that scope creep is a common problem.  Impurity isolation falls into this category – the target impurity is an unknown, present at an uncertain level in a sample, and may not be stable.  It’s a fun problem for the analytical team, but a headache for a project manager. Here are five tips on controlling scope creep in impurity isolation projects:   1)   Start …

Continue reading

Life Science Marketing Radio Interviews Olga Torres

In an inherently highly technical and highly customized contract research space, Olga Torres, Director of Marketing at Averica, developed a marketing plan that very successfully engages people based on Averica’s online presence.  In the Life Science Marketing Radio interview, Olga shares the importance of marketing for a niche life science business and lessons learned along the way to digital credibility. Click to link to podcast page, containing audio and transcript.   Life Science Marketing Radio, hosted …

Continue reading

Averica Answers – What Percent Recovery Can I Expect?

In this video, Jeff Kiplinger discusses the factors that can influence recovery when using chromatography for purification. Well, we’d like to be able to give everyone 100% of the material they sent in back.  The problem is when we receive compounds we receive compounds of different qualities.  The purity of the material that you send in can have an impact on how much you actually recover. For example, if you sent a salt form and we sent back a free …

Continue reading

Averica Answers – What Is Scalable Separation?

“What is Scalable Separation” briefly describes what  we mean when we talk about scalable separation. When we say scalable separations.  What we mean is that we develop each separation method so that it is scalable.  In other words, if you start with 100mg of compound that you need purified for some preliminary testing work – we can take that same separation method to 1g, 10g, 100g’s for advanced testing work.  So when I say scalable separation, what I mean is …

Continue reading

LabTube Meets – Mickey Rego

LabTube houses a global of collection of scientific videos.  Their “LabTube Meets” segment interviews scientists about research, trends and technical innovations.  At Pittcon 2016 LabTube spoke with Mickey Rego about his presentation discussing ways prep chromatography can reduce risk in the early stages of drug development.Discover other great videos from Pittcon 2016, and scientists around the world, by visiting LabTube’s site.

Continue reading

What Type of Chemist Are You?

Have you ever noticed there isn’t a personality chart for chemists?  There are plenty of chemistry roles in drug development, and we believe certain character traits enhance our ability to excel.  We’ve started this discussion using an alignment plot, and welcome all to join in our fun. Are you a chemist?  Where do you fall on the matrix?  Not a chemist – where would you be?  Want to know where we fall?  Our lab mostly falls into the Lawful/Evil spectrum. …

Continue reading

InformEx: 5 min with Jeff Kiplinger 2016

Among the challenges the industry faces, which do you think are the most pressing?These open ended questions always make me think in big picture terms, and for a scientist this means I’m probably beyond my expertise! I think we need to consider re-inventing an R&D based culture.  The pharmaceutical industry has fallen into a trap similar to Hollywood studios – blockbuster products are so valuable that we can’t really invest in properties that might only earn several hundred million dollars …

Continue reading

Averica Appoints Cynthia Berger, Ph.D., as VP Operations

Marlborough, MA, January 20, 2016 Averica Discovery, an analytical development contract research organization (CRO) with specialized expertise in small molecule analysis and purification, today announced the appointment of Cynthia Berger, Ph.D., to the newly-created position of Vice President of Operations. In her new role, Dr. Berger will directly report to CEO Jeff Kiplinger and is expected to contribute broadly to Averica’s growth and development. “We are excited to welcome Cindy, who will provide significant insight and guidance to our growth as an …

Continue reading